Printer Friendly

'Club Drug' approved by FDA for cataplexy in narcoleptic patients. (Prescribing Highly Restricted).

A drug that has been abused as a recreational drug has received Food and Drug Administration approval to treat cataplectic attacks in people with narcolepsy, with restrictions aimed at preventing abuse.

The drug, sodium oxybate or [gamma]-hydroxybutyrate (GHB), is a central nervous system depressant. Approval for this indication was based on two 4-week studies of almost 200 patients with narcolepsy; most of the patients were also on CNS stimulants.

In one study, patients on 6 g or 9 g per day of sodium oxybate had 10 and 16 fewer attacks per week, respectively, compared with 4 fewer attacks per week with placebo.

The exact mechanism of action on cataplexy is unknown, but it appears to involve improved nighttime sleep. Side effects in trials included confusion, nausea and vomiting, and bedwetting.

Orphan Medical of Minnetonka, Minn., will market the drug under the trade name Xyrem.

GHB was widely available and marketed as a dietary supplement for various claims in health food stores until 1990, when the FDA prohibited its marketing after reports of abuse-related respiratory arrests and deaths.

Since then, GHB has been abused as a recreational drug and has resulted in serious sequelae, including fatalities. It also became known as one of the "date rape drugs.

Because of these problems, the drug was approved with a comprehensive risk management program to limit distribution. The program includes patient and physician registries and availability from a centralized pharmacy.

All patients using the drug will receive a medication guide with information about the drug's proper use, administration, and disposal.

Xyrem has been designated a schedule III drug and cannot be sold, distributed, or provided to any one for any reason other than its approved use.

Cataplectic attacks may affect as many as 25,000 of the estimated 135,000 U.S. narcolepsy patients, according to experts.

A copy of the medication guide and other information on the drug and the risk management program are available at www.fda.gov/cder/drug/infopage/xyrem/default.htm.
COPYRIGHT 2002 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Mechcatie, Elizabeth
Publication:Clinical Psychiatry News
Geographic Code:1USA
Date:Oct 1, 2002
Words:333
Previous Article:Experimental antidepressant appears effective, well tolerated. (Reduced Symptoms).
Next Article:Maternal herpes raises offspring's psychosis risk. (Risk Three to Four Times Higher).
Topics:


Related Articles
FDA Approval of 'Club Drug' for Cataplexy Is Imminent.
GHB and narcolepsy.
Understanding narcolepsy.
Data back broader indication for sodium oxybate: trial results lead Xyrem maker to seek approval of drug for narcolepsy symptoms beyond cataplexy.
Care Trust is putting me to sleep; Funding denied to narcolepsy sufferer.
Sodium oxybate may improve sleep in fibromyalgia patients.
Orexin: a treatment for narcolepsy?
Brain imaging and cataplexy.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters